Erytech Pharma SA (ERYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Erytech Pharma SA (ERYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH132699D
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are intended for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, pancreatic cancer and non hodgkin lymphoma, among others. Erytech provides pipeline products such as eryasp, erymet, erymmune, and others. The company also develops other product candidates which uses encapsulated enzymes to induce tumor starvation. Its technology platform ERYCAPS uses red blood cells to discover therapeutic compounds. Erytech is headquartered in Lyon, France.

Erytech Pharma SA (ERYP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Erytech Pharma SA, Medical Devices Deals, 2012 to YTD 2018 9

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Erytech Pharma Raises USD3.95 Million in Venture Financing 11

Erytech Pharma Secures USD19.24 Million in Venture Funding 12

Partnerships 13

Erytech Pharma Enters into Research Agreement with Queen's University 13

Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 14

Invetech Enters into Agreement with Erytech Pharma 15

Licensing Agreements 16

Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 16

Equity Offering 18

Erytech Pharma Raises USD125 Million in IPO of American Depository Shares 18

Erytech Pharma Raises USD15.9 Million in Private Placement of Shares 20

Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 21

Erytech Pharma Raises USD11 Million in Private Placement of Shares 23

Erytech Pharma Raises USD27 Million in Private Placement of Shares 24

Erytech Pharma Plans to Raise Funds through Public Offering of Shares 26

Erytech Pharma Raises USD38 Million in Private Placement of Shares 27

Erytech Pharma Completes IPO For USD21 Million 28

Erytech Pharma SA-Key Competitors 30

Erytech Pharma SA-Key Employees 31

Erytech Pharma SA-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

May 14, 2018: Erytech Reports First Quarter 2018 Financial Results and Provides Business Update 33

Mar 12, 2018: ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017 35

Nov 06, 2017: ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update 37

Sep 11, 2017: ERYTECH Reports First Half 2017 Financial Results and Provides Business Update 38

May 18, 2017: ERYTECH Provides Business Update and Financial Highlights For Q1 2017 41

Clinical Trials 42

Mar 20, 2017: ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017 42

Jan 17, 2017: ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Figures

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Erytech Pharma SA, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Erytech Pharma SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Erytech Pharma SA, Deals By Therapy Area, 2012 to YTD 2018 8

Erytech Pharma SA, Medical Devices Deals, 2012 to YTD 2018 9

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Erytech Pharma Raises USD3.95 Million in Venture Financing 11

Erytech Pharma Secures USD19.24 Million in Venture Funding 12

Erytech Pharma Enters into Research Agreement with Queen's University 13

Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 14

Invetech Enters into Agreement with Erytech Pharma 15

Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 16

Erytech Pharma Raises USD125 Million in IPO of American Depository Shares 18

Erytech Pharma Raises USD15.9 Million in Private Placement of Shares 20

Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 21

Erytech Pharma Raises USD11 Million in Private Placement of Shares 23

Erytech Pharma Raises USD27 Million in Private Placement of Shares 24

Erytech Pharma Plans to Raise Funds through Public Offering of Shares 26

Erytech Pharma Raises USD38 Million in Private Placement of Shares 27

Erytech Pharma Completes IPO For USD21 Million 28

Erytech Pharma SA, Key Competitors 30

Erytech Pharma SA, Key Employees 31

Erytech Pharma SA, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Erytech Pharma SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com